- Home
- TPG vs AXSM Comparison
TPG vs AXSM Comparison
Compare TPG & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- AXSM
- Stock Information
- Founded
- TPG 1992
- AXSM 2012
- Country
- TPG United States
- AXSM United States
- Employees
- TPG N/A
- AXSM N/A
- Industry
- TPG Investment Managers
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- AXSM Health Care
- Exchange
- TPG Nasdaq
- AXSM Nasdaq
- Market Cap
- TPG 6.2B
- AXSM 5.1B
- IPO Year
- TPG 2022
- AXSM 2015
- Fundamental
- Price
- TPG $52.49
- AXSM $104.39
- Analyst Decision
- TPG Buy
- AXSM Strong Buy
- Analyst Count
- TPG 13
- AXSM 16
- Target Price
- TPG $62.17
- AXSM $170.50
- AVG Volume (30 Days)
- TPG 1.8M
- AXSM 694.5K
- Earning Date
- TPG 08-05-2025
- AXSM 08-04-2025
- Dividend Yield
- TPG 3.33%
- AXSM N/A
- EPS Growth
- TPG N/A
- AXSM N/A
- EPS
- TPG N/A
- AXSM N/A
- Revenue
- TPG $3,710,887,000.00
- AXSM $432,157,000.00
- Revenue This Year
- TPG N/A
- AXSM $62.84
- Revenue Next Year
- TPG $23.44
- AXSM $60.02
- P/E Ratio
- TPG N/A
- AXSM N/A
- Revenue Growth
- TPG 44.34
- AXSM 72.16
- 52 Week Low
- TPG $37.52
- AXSM $72.21
- 52 Week High
- TPG $72.98
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- TPG 63.47
- AXSM 47.95
- Support Level
- TPG $48.75
- AXSM $99.75
- Resistance Level
- TPG $53.02
- AXSM $106.60
- Average True Range (ATR)
- TPG 1.51
- AXSM 3.23
- MACD
- TPG 0.23
- AXSM -0.02
- Stochastic Oscillator
- TPG 95.40
- AXSM 36.79
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.